Shares of Eli Lilly (NYSE: LLY) have climbed an incredible 44% since the end of February. Optimism for its weight-management franchise is heating up, but maybe it's a little too hot already.

Is this pharmaceutical industry giant still a good stock to buy? Let's measure its strengths against its weaknesses to find out.

Last May, Mounjaro earned its first approval, and it's already on pace to deliver $3 billion in revenue this year. That's all the more impressive when you consider that it's only approved to treat patients with type 2 diabetes.

Continue reading

Source Fool.com